KellyEliseDooleyMD
Infectious Disease • Nashville, TNAssistant Professor of Medicine, Johns Hopkins University School of Medicine
Dr. Dooley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 Childrens Way
Nashville, TN 37232Phone+1 615-936-2000
Education & Training
Johns Hopkins UniversityFellowship, Infectious Disease, 2005 - 2008- Johns Hopkins UniversityResidency, Internal Medicine, 1999 - 2002
Duke University School of MedicineClass of 1999
Certifications & Licensure
OR State Medical License 2002 - Present
TN State Medical License 2022 - 2025
MD State Medical License 2006 - 2022
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers Start of enrollment: 2009 Dec 01
- Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers Start of enrollment: 2010 Apr 01
- Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin Start of enrollment: 2012 May 01
- Join now to see all
Publications & Presentations
PubMed
- Development and validation of a liquid chromatography-tandem mass spectrometry assay for the simultaneous analysis of isoniazid and pyrazinamide in cerebrospinal fluid.Sydwell Poulo Maputla, Anton Joubert, Sandra Castel, Marthinus van der Merwe, Edda Zangenberg
Journal of Pharmaceutical and Biomedical Analysis. 2025-03-15 - Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis.Nia Covington, Anne F Luetkemeyer, Marjorie Z Imperial, Rodney Dawson, Yoninah Cramer
Pharmacogenetics and Genomics. 2025-02-12 - Development and Validation of a Time-Varying Correction Factor for QT Interval Assessment in Drug-Resistant Tuberculosis Patients.Thanakorn Vongjarudech, Anne-Gaëlle Dosne, Bart Remmerie, Kelly E Dooley, James C M Brust
International Journal of Antimicrobial Agents. 2025-02-06
Journal Articles
- State of the Art Review of HIV‐TB Coinfection in Special PopulationsEthel D Weld, Kelly E Dooley, Clinical Pharmacology & Therapeutics
Press Mentions
VUMC’s Kelly Dooley Joins Clinical Pharmacology BoardJanuary 13th, 2025- Johns Hopkins School of Medicine Among Clinical Trial Sites Testing COVID-19 TherapiesNovember 18th, 2020
Johns Hopkins Researchers to Present Latest Findings on TB and HIV at CROI 2019March 7th, 2019- Join now to see all
Grant Support
- PK/PD Issues In The Use Of New Therapies For The Treatment Of TuberculosisNational Institute Of Allergy And Infectious Diseases2009–2012
Other Languages
- French
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/kelly-dooley
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
